This idea of palliative chemotherapy is relatively new. ItÃ¢â¬â¢s only in recent years that that alleviation of symptoms has become an important component of clinical trials for cancer research. Chemotherapy is a general term for the use of a chemical agent to stop cancer cells from growing. It can be administered in a variety of ways with the most common being: Orally-pills taken by mouth, IntravenouslyÃ¢â¬âinfused through a vein, TopicallyÃ¢â¬â applied to the skin. Chemotherapy usually refers to chemical agents such as alkylating agents, anti-metabolites, and anti-tumor antibiotics. These chemicals are designed to kill cancer cells and prevent them from growing but they arenÃ¢â¬â¢t biased. They attack healthy cells as well, causing side effects such as nausea, hair loss, and infections. While not technically considered chemotherapy, other drugs may be used palliatively to shrink tumor size and slow cancer growth. They include hormone therapy and immunotherapy. Hormone therapy is the use of hormones to slow cancer growth, such as estrogen to slow cervical cancer, tamoxifen to slow breast cancer, and anti-androgens for prostate cancers. Immunotherapy is designed to stimulate the immune system to better recognize and attack cancer cells. For palliative purposes, most oncologists prefer to try the treatment with the least risk of side effects that would negatively impact quality of life. This means that hormone therapy may be tried before toxic chemotherapies.
Review articles are the summary of current state of understanding on a particular research topic. They analyze or discuss research previously published by scientist and academicians rather than reporting novel research results.
Open access to the scientific literature means the removal of barriers (including price barriers) from accessing scholarly work. There are two parallel âroadsâ towards open access: Open Access articles and self-archiving. Open Access articles are immediately, freely available on their Web site, a model mostly funded by charges paid by the author (usually through a research grant). The alternative for a researcher is âself-archivingâ (i.e., to publish in a traditional journal, where only subscribers have immediate access, but to make the article available on their personal and/or institutional Web sites (including so-called repositories or archives)), which is a practice allowed by many scholarly journals.
Open Access raises practical and policy questions for scholars, publishers, funders, and policymakers alike, including what the return on investment is when paying an article processing fee to publish in an Open Access articles, or whether investments into institutional repositories should be made and whether self-archiving should be made mandatory, as contemplated by some funders.
Last date updated on June, 2021